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Background: Dysregulation of omentin-1, a beneficial adipokine, is thought to play a role in the development of
type 2 diabetes and cardiovascular disease. The objective of this study was to evaluate the relationship between
circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes
or cardiovascular disease, and to determine if sex differences influenced the observed relationships.
Methods: Fasting blood samples were obtained from 93 adults, ages 30–60 years, without type 2 diabetes and/or
cardiovascular disease. Participants were classified as having the metabolic syndrome according to American Heart
Association/National Heart, Lung and Blood Institute criteria. Plasma omentin-1 concentrations were measured using
a commercially-available enzyme-linked immunosorbent assay, and relationships between plasma omentin-1 and
components of the metabolic syndrome were assessed in the entire study cohort, by metabolic syndrome status,
and by sex.
Results: On average, participants were 48 ± 8 years of age, 50.5% were women, 54.8% were Caucasian, and 70%
had the metabolic syndrome. Plasma omentin-1 concentrations did not differ significantly between individuals with
versus without the metabolic syndrome (145.7 ± 70 versus 157.4 ± 79.3 ng/ml, p = 0.50). However, men with the
metabolic syndrome had significantly lower omentin-1 levels than men without the metabolic syndrome
(129.9 ± 66 versus 186.3 ± 84.3 ng/ml, p = 0.03). Plasma omentin-1 concentrations were significantly correlated with
HDL cholesterol in the entire study cohort (r = 0.26; p = 0.01), which was primarily driven by a correlation in men
(r = 0.451, p = 0.002) and participants with the metabolic syndrome (r = 0.36; p = 0.003). Plasma omentin-1
concentrations did not differ significantly between men and women; however men with the metabolic syndrome
had 20% lower plasma omentin-1 levels than women with the metabolic syndrome (p = 0.06).
Conclusion: These data demonstrate that circulating omentin-1 levels are associated with HDL cholesterol, primarily
in men and in the presence of the metabolic syndrome. In addition, sex appears to influence the relationship
between plasma omentin-1 concentrations and components of the metabolic syndrome. Additional studies are
needed to explore sexual dimorphism in circulating omentin-1 levels, and the role of omentin-1 in the metabolic
syndrome.
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Omentin-1 is a 32 kDa adipokine that is primarily secreted
by stromal vascular cells in visceral adipose tissue, and
is expressed to a lesser extent in the heart, lung, and
placenta [1,2]. Omentin-1 is a beneficial adipokine that
enhances insulin-stimulated glucose uptake and triggers
Akt signaling, which mediates downstream effects such
as glucose metabolism [2,3]. Along these lines, dysregu-
lation of omentin-1 secretion is thought to play a role in
the pathophysiology of insulin resistance, inflammation,
endothelial dysfunction, and cardiovascular disease [3].
In clinical studies, circulating omentin-1 concentrations
have been shown to be decreased in patients with obesity,
impaired glucose regulation, polycystic ovary syndrome,
type 1 diabetes, and type 2 diabetes [4-10]. Low circulating
levels of omentin-1 have also been associated with endo-
thelial dysfunction and cardiovascular disease [11-16].
Given these clinical associations, omentin-1 has garnered
attention as a possible contributor to the pathogenesis of
the metabolic syndrome [14,17].
The metabolic syndrome is a clustering of metabolic,
proinflammatory, and prothrombotic factors that increases
the risk of cardiovascular disease and type 2 diabetes
[18-20]. Adipose tissue dysregulation and altered secretion
of numerous adipokines are present in the metabolic
syndrome [20-22]. However, in regards to omentin-1, few
studies have evaluated the relationship between omentin-1
and the metabolic syndrome in patients without concomi-
tant type 2 diabetes and/or cardiovascular disease (termed
“nascent metabolic syndrome” by Jialal et al.) [22,23].
The primary objective of this study was to determine
the relationship between circulating omentin-1 concen-
trations and components of the metabolic syndrome in
adults without type 2 diabetes or cardiovascular disease.
We also sought to determine the influence of sex on the
relationship between omentin-1 and the metabolic
syndrome phenotype in these nondiabetic adults.
Methods
Study population
This study was conducted in nondiabetic subjects between
30 to 60 years of age who were screened for a parent
metabolic syndrome clinical study at the University of
Colorado. The parent study was approved by the Colorado
Multiple Institutional Review Board (COMIRB 07-0817).
All participants provided written informed consent for the
parent study and permission to use their samples in future
research.
Participants were classified as having the metabolic
syndrome if they had three or more components of the
American Heart Association/National Heart, Lung and
Blood Institute (AHA/NHLBI) criteria: waist circum-
ference ≥ 102 cm in men or ≥ 88 cm in women; triglyc-
erides ≥ 150 mg/dL; high-density lipoprotein (HDL)cholesterol < 40 mg/dL in men or < 50 mg/dL in women;
systolic blood pressure ≥ 130 mm Hg and/or diastolic blood
pressure ≥ 85 mm Hg and/or on antihypertensive drug
therapy, or fasting plasma glucose (≥ 100 mg/dL) [18].
Participants were excluded for a current or past history
of cardiovascular disease, congestive heart failure, stroke
or transient ischemic attack, type 1 or type 2 diabetes,
gastric bypass surgery, Cushing’s syndrome, liver or kid-
ney disease, pancreatitis, active malignancy, HIV, preg-
nancy, or lactation. Participants were also excluded for
fasting plasma glucose ≥ 126 mg/dL, systolic blood pres-
sure ≥ 180 mm Hg, diastolic blood pressure ≥ 110 mm Hg,
triglycerides ≥ 800 mg/dL, liver enzymes ≥ 2 times the upper
limit of normal, and/or serum creatinine ≥ 1.4 mg/dL.
Medication exclusions included anti-diabetic medications,
fibrates, nicotinic acid, systemic glucocorticoids, aspirin,
non-steroidal anti-inflammatory drugs, hormonal con-
traceptives, estrogen hormone replacement therapy, HIV
medications, calcineurin inhibitors, atypical antipsychotics,
phenytoin and/or weight loss medications.
Anthropometric and laboratory measurements
Participants were weighed in a gown and without shoes.
Waist circumference was measured halfway between
the lower rib and the iliac crest using a cloth tape
measure. Blood pressure was measured with an auto-
mated monitor two times after a 5-minute rest period,
and the average of the two blood pressures was used in
study analyses. Blood samples (EDTA) were drawn in
the fasting state between 7:00 AM and 11:00 AM.
Blood samples were centrifuged and plasma was col-
lected and stored at -80°C until analytical processing.
Plasma omentin-1 concentrations were measured in dupli-
cate using a commercially-available enzyme-linked immu-
nosorbent assay (ELISA), using the protocol provided by
the manufacturer (Millipore; Billerica, MA, USA). In total,
five ELISA assays were run, with samples on four of the
five plates being the first freeze-thaw, and samples on one
plate being the second freeze-thaw. Briefly, six standard
concentrations of 2 ng/ml, 4 ng/ml, 10 ng/ml, 20 ng/ml,
40 ng/ml, and 100 ng/ml were prepared. Patient samples
were diluted 4-fold with assay buffer, per the protocol.
Proprietary matrix solution and/or assay buffer were
added to the plate. Standards, two quality controls, and
patient samples were then added in duplicate to the
appropriate wells. An antibody solution mixture, which
contained a 1:1 mixture of capture and detection antibody,
was added to each well and the plate was incubated at
room temperature on an orbital shaker at moderate speed
for 2 hours. After incubation, wells were decanted and
washed, and an enzyme solution was added. The plate was
incubated on an orbital shaker at moderate speed for
30 minutes. Following this second incubation, the wells
were decanted and washed thoroughly. A substrate
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orbital shaker for 12 minutes, followed by the addition of
a stop solution. Absorbance was read at 450 nm and
590 nm within five minutes. A sigmoidal 4-parameter
logistic equation was used to analyze the data. The results
of the patient samples were multiplied by the sample dilu-
tion factor of 4, per the manufacturer’s instructions. The
lower limit of detection of the assay was 0.23 ng/ml. The
intra- and inter-day coefficients of variation were 4.7% and
3.7%, respectively. Plasma glucose, total cholesterol, HDL
cholesterol, and triglycerides were measured enzymatically
using an Olympus AU400e Chemistry Analyzer (Olympus
America Inc., Center Valley, PA, USA). LDL cholesterol
was calculated from total cholesterol, HDL cholesterol,
and triglycerides using the Friedewald formula [24].
Statistical analyses
The primary endpoint of the study was the difference in
plasma omentin-1 concentrations between participants
with versus without the metabolic syndrome, and the
correlation between plasma omentin-1 concentrations
and metabolic and clinical variables in the entire study
population. Data were collected and managed using Re-
search Electronic Data Capture (REDCap) tools hosted
at the University of Colorado Denver [25]. Data are pre-
sented as mean ± standard deviation or median (range).
Non-normally distributed data were log-transformed prior
to analysis, and then back-transformed for numerical
data presentation. Pearson’s correlations were used to
determine the relationship between plasma omentin-1Table 1 Baseline demographics of study population
Characteristic Total population (n = 93) Metabo
Omentin-1 (ng/mL) 149.2 ± 72.7 145.7 ± 7
Sex (women/men) 47/46 32/33
Age (years) 48 ± 8 49 ± 8
Current smokers 24 (25.8%) 16 (24.6%
BMI (kg/m2) 31.3 ± 4.7 32.1 ± 4.0
Weight (kg) 91.6 ± 15.6 93.8 ± 13
Systolic blood pressure (mm Hg) 129 ± 14 132 ± 14
Diastolic blood pressure (mm Hg) 83 ± 12 85 ± 11
Waist circumference (cm) 106.0 ± 11.8 108.6 ± 9
Fasting plasma glucose (mg/dL) 93 ± 9 95 ± 10
Impaired fasting glucose 28 (30.1%) 26 (40.0%
Total cholesterol (mg/dL) 187 ± 35 187 ± 37
LDL cholesterol (mg/dL) 110 ± 29 109 ± 30
HDL cholesterol (mg/dL) 44 ± 11 41 ± 10
Triglycerides (mg/dL) 166 ± 83 187 ± 80
White blood cell count (x 109/L) 6.5 ± 2.0 6.4 ± 1.8
Data are expressed as mean ± standard deviation or number (%). aP values are for c
omentin-1 concentrations, expressed as median (interquartile range), were 137.2 ng
184.8 ng/ml) in participants with the metabolic syndrome, and 137.4 ng/ml (104.5 tconcentrations and components of the metabolic syn-
drome. Independent t tests or ANOVA were used to
compare omentin-1 concentrations between 2 groups
or 3 or more groups, respectively. Data were analyzed
with SPSS version 20 software (IBM, New York, NY,
USA). A p value <0.05 was used as the level of significance
for the primary endpoint. Other comparisons (e.g., sexual
dimorphism) were not corrected for multiple testing and
thus should be considered exploratory in nature.
Results
Baseline characteristics and metabolic syndrome
phenotype
The study population consisted of 93 participants with-
out type 2 diabetes or cardiovascular disease who were
screened for the parent metabolic syndrome study.
Baseline demographics of the entire study cohort, and
in participants with and without the metabolic syn-
drome, are shown in Table 1. On average, participants
were 48 ± 8 years of age, 50.5% were women, and 26%
were current smokers. The racial distribution of the
study population was 54.8% Caucasian, 26.9% African
American, 5.4% American Indian/Eskimo/Aleutian, 2.2%
Asian/Pacific Islander, and 10.8% other. The ethnic make-
up of the study population was 16.1% Hispanic. In the
metabolic syndrome group, 11 (17%) participants were on
statins and 32 (49%) participants were on antihyperten-
sive medication(s) (n = 21 ACE/ARBs, n = 15 potassium-
sparing or thiazide diuretics, n = 8 beta blockers, and n = 2
calcium channel blockers). In participants without thelic syndrome (n = 65) No metabolic syndrome (n = 28) aP value
0.0 157.4 ± 79.3 0.50
15/13 0.70
45 ± 8 0.02
) 8 (12.3%) 0.69
29.3 ± 5.6 0.02
.4 86.4 ± 19.2 0.01
121 ± 12 0.001
77 ± 13 0.002
.5 99.9 ± 14.4 0.001
89 ± 8 0.001
) 2 (7.1%) 0.002
185 ± 30 0.73
111 ± 25 0.80
50 ± 12 <0.001
118 ± 71 <0.001
6.7 ± 2.4 0.60
omparisons of metabolic syndrome versus no metabolic syndrome. Plasma
/ml (94.2 to 186.8 ng/ml) in the total population, 133.1 ng/ml (93.5 to
o 196.2 ng/ml) in participants without the metabolic syndrome.
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6 (21%) were on antihypertensive medication(s) (n = 5
ACE/ARBs, n = 2 beta-blockers, n = 2 potassium-sparing
or loop diuretics, and n = 0 calcium channel blockers). The
median plasma omentin-1 concentration was 137.2 ng/ml
and the full range was 22.8 to 376.7 ng/ml. Mean plasma
omentin-1 concentrations were higher in African Americans
(164.5 ± 70.2 ng/ml) than in Caucasians (138.5 ± 75.9 ng/ml),
although this finding was not statistically significant
(p = 0.10).
The metabolic syndrome was present in 70% of the study
population, and 30% of participants had impaired fasting
glucose. As expected, age, body mass index (BMI), body
weight, systolic blood pressure, diastolic blood pressure,
waist circumference, fasting plasma glucose, and triglycer-
ides were significantly higher, while HDL cholesterol was
significantly lower, in individuals with versus without the
metabolic syndrome (Table 1). Mean plasma omentin-1
concentrations did not differ significantly between par-
ticipants with versus without the metabolic syndrome
(145.7 ± 70.0 ng/ml versus 157.4 ± 79.3 ng/ml, respect-
ively; p = 0.50), nor by number of metabolic syndrome
components (p = 0.82, Figure 1). Mean plasma omentin-
1 concentrations were 183.1± 66.1 ng/ml in normal
weight (n = 9, BMI < 25 kg/m2), 153.3± 88.4 ng/ml in
overweight (n = 28, BMI 25.0-29.9 kg/m2), and 141.8±
64.1 ng/ml in obese (n = 56, BMI ≥ 30 kg/m2) partici-
pants (p = 0.31). In participants without the metabolic
syndrome, mean plasma omentin-1 concentrations were
lower in those who were overweight or obese (n = 20,
149.0 ± 83.1 ng/ml) compared with those who were normal
weight (n = 8, 178.6 ± 69.1 ng/ml), although this was notFigure 1 Plasma omentin-1 concentrations according to the
number of components of the metabolic syndrome. The vertical
boxes contain the interquartile range for the respective data. The
horizontal solid lines in the boxes represent the median value of the
data. The whiskers extending from the bottom and top of the boxes
indicate the 5th and 95th percentiles of the data, respectively.statistically significant (p = 0.27). In participants with the
metabolic syndrome, there was only one normal weight
individual, which precluded any statistical comparisons
between BMI categories. When the analysis was isolated
to only overweight or obese participants, mean plasma
omentin-1 concentrations did not differ significantly be-
tween those with (n = 64) versus without (n = 20) the
metabolic syndrome (144.6 ± 69.9 versus 149.0 ± 83.1,
respectively, p = 0.88). Mean plasma omentin-1 concentra-
tions also did not differ significantly between non-smokers
and smokers (148.5 ± 69.5 ng/ml versus 151.5 ± 82.6 ng/ml,
respectively, p = 0.99). When the data were separated by
smoking status, mean plasma omentin-1 concentrations
did not differ significantly between non-smokers with
(n = 49) versus without (n = 20) the metabolic syndrome
(144.4 ± 73.1 ng/ml versus 158.3 ± 60.4 ng/ml, respect-
ively, p = 0.23). Likewise, mean plasma omentin-1 concen-
trations did not differ significantly between smokers with
(n = 16) versus without (n = 8) the metabolic syndrome
(149.7 ± 61.3 ng/ml versus 155.1 ± 119.7 ng/ml, respect-
ively, p = 0.56).
Correlations between plasma omentin-1 concentrations
and metabolic and clinical variables in the entire
population
Correlations between plasma omentin-1 concentrations
and components of the metabolic syndrome and clinical
variables are shown in Table 2. Plasma omentin-1 concen-
trations were significantly correlated with HDL cholesterol
in the entire study cohort (r = 0.26, p = 0.01, Figure 2A).
This correlation remained significant after controlling
for BMI (r = 0.25, p = 0.02). Plasma omentin-1 concen-
trations were also modestly correlated with triglycerides
(r = −0.195) and systolic blood pressure (r = 0.198), althoughTable 2 Bivariate correlations of plasma omentin-1
concentrations and clinical/metabolic variables in the
study population (n = 93)
Omentin-1 (ng/mL)
Variable Correlation coefficient (r) P value
Age (years) 0.143 0.17
Weight (kg) −0.067 0.52
BMI (kg/m2) −0.081 0.44
Systolic blood pressure (mm Hg) 0.198 0.06
Diastolic blood pressure (mm Hg) 0.109 0.30
Waist circumference (cm) −0.139 0.18
Fasting plasma glucose (mg/dL) 0.030 0.78
Total cholesterol (mg/dL) 0.068 0.52
LDL cholesterol (mg/dL) 0.087 0.41
HDL cholesterol (mg/dL) 0.260 0.01
Triglycerides (mg/dL) −0.195 0.06
White blood cell count (x 109/L) −0.063 0.55
Figure 2 Relationship between plasma omentin-1 concentrations and HDL cholesterol. A. Scatterplot with regression line of the correlation
between plasma omentin-1 concentrations and HDL cholesterol levels in the entire study population (n = 93). B. Scatterplot with regression line
of the correlation between plasma omentin-1 concentrations and HDL cholesterol levels in participants with the metabolic syndrome (n = 65).
C. Scatterplot with regression line of the correlation between plasma omentin-1 concentrations and HDL cholesterol levels in men (n = 46).
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for both variables). When the study cohort was stratified
based on the presence or absence of the metabolic
syndrome (Table 3), plasma omentin-1 concentrations
remained significantly correlated with HDL cholesterol
in participants with the metabolic syndrome (r = 0.36,
p = 0.003, Figure 2B). Controlling for BMI did not
change the magnitude or significance of this finding. In
contrast, plasma omentin-1 concentrations were not
significantly correlated with any metabolic or clinical
variables in participants without the metabolic syndrome.
Relationship between plasma omentin-1 concentrations
and sex
BMI and HDL cholesterol were significantly higher, while
triglycerides were significantly lower, in women com-
pared with men (Table 4). However, plasma omentin-1Table 3 Bivariate correlations of plasma omentin-1 concentra
syndrome status
Omentin-1 (ng/mL)
Metabolic syndrome (n = 65)




Systolic blood pressure (mm Hg) 0.226
Diastolic blood pressure (mm Hg) 0.144
Waist circumference (cm) −0.110
Fasting plasma glucose (mg/dL) 0.025
Total cholesterol (mg/dL) 0.150
LDL cholesterol (mg/dL) 0.169
HDL cholesterol (mg/dL) 0.360
Triglycerides (mg/dL) −0.179
White blood cell count (x 109/L) −0.076concentrations did not differ significantly between men
and women (Table 4). In men, plasma omentin-1 concen-
trations were significantly correlated with HDL cholesterol
(r = 0.451, p = 0.002, Figure 2C), triglycerides (r = −0.312;
p = 0.04), and BMI (r = −0.314, p = 0.03). After controlling
for BMI, only HDL cholesterol remained significantly cor-
related with omentin-1 levels in men (r = 0.40, p = 0.006).
Plasma omentin-1 concentrations were not significantly
correlated with any metabolic or clinical variables in
women (data not shown).
Men and women were further stratified based on the
presence or absence of the metabolic syndrome (Table 4).
Men with the metabolic syndrome had significantly
lower plasma omentin-1 concentrations than men with-
out the metabolic syndrome (p = 0.03). Men with the
metabolic syndrome also had about 20% lower plasma
omentin-1 levels than women with the metabolictions and clinical/metabolic variables by metabolic
Omentin-1 (ng/mL)
No metabolic syndrome (n = 28)



































Omentin-1 (ng/mL) 152.6 ± 70.7 145.8 ± 75.2 0.55 162.0 ± 71.2 132.4 ± 67.6 0.19 129.9 ± 66.0 186.3 ± 84.4 0.03
Age (years) 47 ± 8 48 ± 8 0.67 48 ± 8 45 ± 8 0.28 50 ± 8 44 ± 9 0.04
Current smokers 11 (23.4%) 13 (28.2%) 0.59 7 (21.8%) 4 (26.7%) 0.73 9 (27.3%) 4 (30.8%) 1.00
BMI (kg/m2) 32.4 ± 4.6 30.1 ± 4.5 0.02 33.1 ± 4.2 31.0 ± 5.4 0.16 31.2 ± 3.7 27.2 ± 5.3 0.005
Weight (kg) 89.0 ± 15.4 94.2 ± 15.6 0.10 92.2 ± 15.4 82.4 ± 13.5 0.03 95.4 ± 11.2 91.1 ± 23.9 0.36
Systolic blood
pressure (mm Hg)
128 ± 16 130 ± 13 0.48 132 ± 16 119 ± 13 0.01 132 ± 13 124 ± 11 0.040
Diastolic blood
pressure (mm Hg)
81 ± 13 85 ± 11 0.10 83 ± 12 75 ± 14 0.04 87 ± 10 79 ± 11 0.03
Waist circumference (cm) 104.3 ± 11.1 107.7 ± 12.4 0.16 106.8 ± 10 98.9 ±11.6 0.02 110.4 ± 8.7 101.0 ± 17.4 0.08
Fasting plasma
glucose (mg/dL)
93 ± 9 93 ± 10 0.89 95 ± 9 89 ± 7 0.03 95 ± 10 88 ± 8 0.02
Impaired fasting glucose 13 (27.7%) 15 (32.6%) 0.60 12 (37.5%) 1 (6.7%) 0.04 14 (42.4%) 1 (7.7%) 0.04
Total cholesterol (mg/dL) 184 ± 34 190 ± 36 0.43 185 ± 39 181 ± 22 0.71 190 ± 36 189 ± 39 0.94
LDL cholesterol (mg/dL) 107 ± 27 113 ± 30 0.33 108 ± 28 104 ± 23 0.61 110 ± 32 119 ± 26 0.39
HDL cholesterol (mg/dL) 47 ± 13 40 ± 8 <0.001 44 ± 10 55 ± 14 0.002 38 ± 8 44 ± 7 0.01
Triglycerides (mg/dL) 146 ± 79 186 ± 84 0.02 163 ± 80 109 ± 64 0.01 209 ± 75 128 ± 79 <0.001
White blood cell
count (x 109/L)
6.8 ± 2.3 6.2 ± 1.6 0.34 6.7 ± 2.3 7.0 ± 2.5 0.63 6.2 ± 1.2 6.4 ± 2.3 0.89
Data are expressed as mean ± standard deviation or number (%). aP values for comparisons of all women versus all men. bP values for comparisons of women
with metabolic syndrome versus women without metabolic syndrome. cP values for comparisons of men with metabolic syndrome versus men without metabolic
syndrome. Plasma omentin-1 concentrations, expressed as median (interquartile range), were 133.1 ng/ml (102.2 to 212.3 ng/ml) in all women, 138.2 ng/ml (90.5
to 181.1 ng/ml) in all men, 154.0 ng/ml (109.0 to 217.9 ng/ml) in women with the metabolic syndrome, 119.7 ng/ml (89.4 to 155.4 ng/ml) in women without the
metabolic syndrome, 118.9 ng/ml (77.7 to 173.1 ng/ml) in men with the metabolic syndrome, and 177.3 ng/ml (132.0 to 229.2 ng/ml) in men without the
metabolic syndrome.
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centrations did not differ significantly between women
with versus without the metabolic syndrome (p = 0.19).
Discussion
In this study, we sought to determine the relationship
between circulating omentin-1 levels and components of
the metabolic syndrome in adults without type 2 diabetes
or cardiovascular disease. We also evaluated whether a
sexual dimorphism existed for these relationships. HDL
cholesterol was found to be a significant correlate of
plasma omentin-1 concentrations in the entire study co-
hort, which was primarily driven by an association in men
and in individuals with the metabolic syndrome. Circulat-
ing omentin-1 levels did not differ by metabolic syndrome
status nor between men and women. When the data were
stratified by sex, men with the metabolic syndrome had
significantly lower omentin-1 levels than men without the
metabolic syndrome and women with the metabolic syn-
drome. Together, these data demonstrate that omentin-1
is associated with HDL cholesterol, and that sex may in-
fluence patterns of association between omentin-1 con-
centrations and components of the metabolic syndrome
phenotype.The correlation between HDL cholesterol and omentin-
1 has been previously described in the settings of obesity,
metabolic syndrome, diabetes, and cardiovascular disease
[4,8,10,12,13,17,26]. However, unlike other studies, we
found that the association was primarily in men and in the
presence of the metabolic syndrome. These observations
are in line with previous knowledge that low HDL levels
predominate in men and are a defining component of
the metabolic syndrome phenotype. However, the physio-
logic mechanisms underlying the relationship between
omentin-1 and HDL cholesterol are less clear. A plausible
explanation is that dysregulation of omentin-1 may ad-
versely affect insulin signaling and regulation, thereby
altering HDL production [10,27]. A similar situation has
been described for the beneficial adipokine, adiponectin
[28]. Decreased adiponectin levels have been associated
with decreased HDL cholesterol and an increased risk of
cardiovascular disease in some studies [29-32]. Although
few prospective data exist for omentin-1, some studies
suggest that circulating omentin-1 concentrations are as-
sociated with atherosclerosis and coronary artery disease
in different patient populations [12-14,16].
We did not observe a difference overall in circulating
omentin-1 concentrations between individuals with versus
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trast to Jialal et al. who reported that plasma levels of
omentin-1 were 41% lower in patients with nascent
metabolic syndrome as compared with controls [17].
The discrepancy is likely due to differences in study de-
signs (e.g., inclusion and exclusion criteria) and popula-
tion demographics. For example, Jialal et al. matched
cases and controls on the basis of gender and age, while
we did not; thus there may be more variability in our
population, which may have obscured statistical signifi-
cance [17]. Second, in the study by Jialal et al., 7% of
patients in the metabolic syndrome group received anti-
hypertensive medications, while in our study, 49% of
patients in the metabolic syndrome group were taking
antihypertensive medications. To the best of our know-
ledge, no clinical studies have comprehensively evalu-
ated the effects of various antihypertensive medications
on plasma omentin-1 concentrations. It is possible that
the concomitant drug therapy in our study may have
attenuated any associations between omentin-1 and
components of the metabolic syndrome. Third, the study
population by Jialal et al. was made up of 91% women,
while our population was made up of 51% women. The
inclusion of more men in our population may have con-
tributed to greater variability in our population overall.
Lastly, our metabolic syndrome group was younger and
had a lower mean BMI than the previous study. A dif-
ferent study by Shibata et al. reported that circulating
omentin-1 levels were inversely correlated with the
number of metabolic risk factors in Japanese men who
were taking no medications [33]. The demographics of
that population were vastly different than ours, particu-
larly in terms of race and concomitant medications,
which may explain differences in the study findings.
Taken together, compared with the published literature,
our study encompasses a more heterogeneous metabolic
syndrome population.
A possible sexual dimorphism in circulating omentin-1
levels has been previously reported but, to the best of our
knowledge, our study is the first to compare omentin-1
levels by sex and nascent metabolic syndrome status. We
observed that circulating omentin-1 did not differ between
men and women in the entire study cohort; however,
men with the metabolic syndrome had about 20% lower
plasma omentin-1 levels than women with the metabolic
syndrome. When we analyzed our data by sex, plasma
omentin-1 levels were 30% lower in men with versus with-
out the metabolic syndrome, yet did not differ between
women. These findings suggest possible sex differences in
omentin-1 regulation (discussed below). Other studies
have reported decreased circulating omentin-1 levels in
patients with the metabolic syndrome; however, direct
comparisons with these studies are difficult given the
presence of type 2 diabetes, cardiovascular disease, and/or use of different metabolic syndrome criteria in the
populations [13,14]. de Souza Batista et al. were the first
to show that, in healthy Amish subjects, women had
higher circulating omentin-1 concentrations than men [4].
Moreno-Navarrete et al. also showed that sex was an inde-
pendent predictor of circulating omentin-1 levels in obese
subjects [34]. In contrast, other studies have found no sig-
nificant differences in plasma omentin-1 levels between
men and women in various clinical populations [10,13,35].
Although the relationship between sex and circulating
omentin-1 concentrations is not entirely consistent
between studies, it has been hypothesized that sexual
dimorphism in circulating adipokines, such as omentin-1,
may be a result of differences in the pattern of body fat
distribution between men and women (e.g., android versus
gynoid), inherent sex differences in adipose tissue gene
expression and function, or the impact of sex hormones
on omentin-1 regulation [10,36,37]. In this regard, Luque-
Ramirez et al. recently reported that circulating omentin-1
levels were negatively correlated with free testosterone
concentrations in normal weight and overweight subjects
[36]. These data are consistent with situations of andro-
gen excess (e.g., polycystic ovary syndrome), in which
omentin-1 levels have been shown to be lower than
controls, and inversely associated with circulating an-
drogen levels [7,8,38,39]. Additional in vitro and in vivo
studies are needed to further explore the mechanisms
underlying putative sex differences in omentin-1 regula-
tion in patients with nascent metabolic syndrome. Pro-
spective, longitudinal studies are also needed to determine
whether circulating omentin-1 concentrations are an inde-
pendent and robust predictor of diabetes, subclinical
inflammation, and/or cardiovascular risk [40].
Limitations
There are limitations of our study that deserve to be ac-
knowledged. First, our study employed a cross-sectional
design; therefore, we could not evaluate the causal rela-
tionship between plasma omentin-1 levels and compo-
nents of the metabolic syndrome phenotype. Second,
we did not prospectively obtain insulin or adiponectin
measurements in our study. Thus, we could not evalu-
ate associations of omentin-1 with insulin resistance or
adiponectin. Third, the analysis of sex differences in
omentin-1 concentrations was a secondary objective of
our study. As such, we did not measure sex hormones
nor did we control for menopausal status. Third, we
observed considerable variability in plasma omentin-1
concentrations in our study (range, 22.8 to 376.7 ng/mL).
Unfortunately, few published studies have presented the
full range of plasma omentin-1 concentrations in their
respective populations. As such, it is difficult for us to
directly compare the range of omentin-1 concentrations
observed in our study with other groups. It is also
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were analyzed after a second freeze-thaw cycle. This
may have led to omentin-1 degradation and lower
omentin-1 levels in our study population. However, if
we compare calculated coefficients of variation (CVs) of
omentin-1 levels between studies, it appears that the
omentin-1 CVs in our study were comparable to other
groups. These data suggest that there is substantial vari-
ability in plasma omentin-1 concentrations. The reasons
for this are unclear, but may be due to differences in la-
boratory methodologies and ELISA assays, patient popula-
tions, participant fat mass and distribution, concomitant
medications, social factors, environmental factors, and/or
genetics. Lastly, our sample size was small, which may
have limited power to detect significant associations,
particularly in smaller subgroups.
Conclusions
Taken together, our data suggest that omentin-1 is asso-
ciated with HDL cholesterol and that sex influences the
relationship between circulating omentin-1 levels and
components of the metabolic syndrome phenotype.
Additional studies are needed to further explore sexual
dimorphism in circulating omentin-1 levels, and the ability
of omentin-1 to predict the future development of type 2
diabetes and cardiovascular disease in nondiabetic patients
with the metabolic syndrome.
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